Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer

Pancreatic cancer is one of the most aggressive and lethal types of cancer, and more effective therapeutic agents are urgently needed. Overexpressed cell surface antigens are ideal targets for therapy with monoclonal antibody (mAb)-based drugs, but none have been approved for the treatment of pancre...

Descripción completa

Detalles Bibliográficos
Autores principales: Arias-Pinilla, Gustavo A., Dalgleish, Angus G., Mudan, Satvinder, Bagwan, Izhar, Walker, Anthony J., Modjtahedi, Helmout
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929441/
https://www.ncbi.nlm.nih.gov/pubmed/29731998
http://dx.doi.org/10.18632/oncotarget.25017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929441/
https://www.ncbi.nlm.nih.gov/pubmed/29731998
http://dx.doi.org/10.18632/oncotarget.25017

Ejemplares similares